severe asthma
Respiratory · 2026–2026
1decision
1medicine
0carried consumer input
0individual submissions
No submission for this condition has carried consumer input, including the one made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| omalizumab Treatment of uncontrolled severe asthma (USA), uncontrolled severe allergic asthma (USAA), and severe chronic spontaneous urticaria (CSU) in eligible patients.… | Mar 2026 | Recommended with restriction | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.